ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0384

Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR

Bas Dijkshoorn1, Ting Wang2, Gerdur Maria Grondal3, Daisy Vedder4, Anna Rudin5, Dan Nordstrom6, Bjorn Gudbjornsson7, Kristina Lend8, Till Uhlig9, Espen Haavardsholm9, Merete L Hetland10, Marte Schrumpf Heiberg11, Mikkel Østergaard12, Kim Horslev-Petersen13, John Lampa14, Ronald van Vollenhoven15, Christian Lood2 and Michael Nurmohamed16, 1Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, 2University of Washington, Seattle, WA, 3Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 4Reade, Amsterdam, Netherlands, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Helsinki University Hospital, Helsinki, Finland, 7Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 8Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 9Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 10Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 11Diakonhjemmet Hospital, Oslo, Norway, 12Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 13Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 14Stockholm County, Hãsselby, Sweden, 15Amsterdam University Medical Centers, Amsterdam, Netherlands, 16Amsterdam University Medical Centers, Kortenhoef, Netherlands

Meeting: ACR Convergence 2023

Keywords: Biologicals, Cell Death, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The formation of neutrophil extracellular traps (NETs) with extrusion of nuclear, granular and cytosolic components from a dying neutrophil, has been described extensively in patients with rheumatoid arthritis (RA), and linked to generation of autoantigens (e.g. citrullinated proteins), inflammation and organ damage. Thus far there have been very few studies describing the effect of treatment in patients with RA on NET formation, and no studies comparing the effects of treatment strategies in (very) early RA. The objective of the study is to assess the effects of different initial treatments on NET formation in patients with early RA.

Methods: NORD-STAR is an international, multicenter, open-label, assessor-blinded, phase 4 study where patients with newly diagnosed RA started methotrexate (MTX) and were randomized 1:1:1:1 to a) conventional treatment (either prednisolone tapered to 5mg/day, or sulfasalazine combined with hydroxychloroquine and intra-articular corticosteroids), b) certolizumab pegol, c) abatacept, or d) tocilizumab1. This study is a spin-off from the main NORD-STAR study measuring neutrophil biomarkers MPO-DNA (Myeloperoxidase-DNA; NETs) and calprotectin in 24 consecutive Dutch participants and 94 Swedish patients at baseline, 12 weeks and 24 weeks after the start of the treatment. Statistical analysis was done using the Wilcoxon Signed Rank test for paired samples and independent samples median test to compare patients to healthy controls in SPSS version 28.

Results: At baseline patients had elevated levels of NETs and neutrophil activation compared to healthy controls as indicated by calprotectin (median 1080ng/ml vs 133ng/ml, p< 0.001) and elevated MPO-DNA (median 7185pM vs 3976pM, p< 0.001). Both of the biomarkers decreased significantly at 12 and 24 weeks after treatment in the total group demonstrating reduced neutrophil activity and NET formation. After 24 weeks of treatment, calprotectin was significantly reduced in all groups by up to 93% (Table 1). MPO-DNA showed a more modest reduction of up to 13%, and was relatively similar in all groups, although the reduction in MPO-DNA did not reach statistical significance in the tocilizumab group.

Conclusion: These results indicate highly elevated neutrophil activation and NET formation in recently diagnosed RA patients. All four treatments studied here reduced these detrimental processes within 3 months. The calprotectin reduction seen in this study is in line with an earlier spin-off study2. The rapid decline in these markers may have contributed to the minimal radiological progression that was seen in the NORD-STAR trial.

References:
[1] Hetland M et al. BMJ. 2020
[2] Stevens D et al. Ann Rheum Dis. 2022

Supporting image 1

Supporting image 2


Disclosures: B. Dijkshoorn: Galapagos, 2, Novartis, 2; T. Wang: None; G. Grondal: None; D. Vedder: None; A. Rudin: AstraZeneca, 12, financial support; D. Nordstrom: AbbVie/Abbott, 2, BMS, 2, Lilly, 2, MSD, 2, Novartis, 2, Pfizer, 2, UCB, 2; B. Gudbjornsson: Nordic-Pharma, 6, Novartis, 2, 6; K. Lend: None; T. Uhlig: Galapagos, 2, 6, Lilly, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; E. Haavardsholm: AbbVie/Abbott, 2, Boehringer-Ingelheim, 2, Eli Lilly, 2, Gilead, 2, Pfizer, 6, UCB, 6; M. Hetland: AbbVie/Abbott, 1, 5, Bristol-Myers Squibb(BMS), 5, Danbio, 12, MLH has chaired the steering committee of the Danish Rheumatology Quality Registry (DANBIO, DRQ), which receives public funding from the hospital owne, Eli Lilly, 5, MEDAC, 6, Novartis, 5, Pfizer, 5, 6, Sandoz, 5, 6; M. Schrumpf Heiberg: Roche, 6; M. Østergaard: AbbVie, 2, 5, 6, Amgen, 5, Boehringer-Ingelheim, 2, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, Hospira, 2, 6, Janssen, 2, 6, MEDAC, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Novo Nordisk, 2, 6, Orion, 2, 6, Pfizer, 2, 6, Regeneron, 2, 6, Roche, 2, 6, Sandoz, 2, 6, Sanofi, 2, 6, UCB, 2, 6; K. Horslev-Petersen: None; J. Lampa: None; R. van Vollenhoven: AbbVie, 2, 6, AstraZeneca, 2, 5, 6, Biogen, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Galapagos, 2, 5, 6, GlaxoSmithKline, 6, Janssen, 2, 6, MSD/Merck Sharp and Dohme, 5, Novartis, 5, Pfizer, 2, 5, 6, RemeGen, 2, Roche, 5, Sanofi, 5, UCB, 2, 5, 6; C. Lood: Amytryx, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Citryll, 2, Eli Lilly, 5, Gilead, 5, Horizon Therapeutics, 5, Pfizer, 5, Redd Pharma, 5, 11; M. Nurmohamed: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Celgene, 2, 5, 6, Galapagos, 2, 5, Janssen, 2, 5, 6, Menarini, 2, 5, 6, Merck/MSD, 2, 5, 6, Mundipharma, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, Sanofi, 2, 5, 6, UCB, 2, 5, 6.

To cite this abstract in AMA style:

Dijkshoorn B, Wang T, Grondal G, Vedder D, Rudin A, Nordstrom D, Gudbjornsson B, Lend K, Uhlig T, Haavardsholm E, Hetland M, Schrumpf Heiberg M, Østergaard M, Horslev-Petersen K, Lampa J, van Vollenhoven R, Lood C, Nurmohamed M. Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/targeting-net-formation-in-early-ra-patients-a-spin-off-study-from-the-nord-star/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-net-formation-in-early-ra-patients-a-spin-off-study-from-the-nord-star/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology